Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1085-1093

  Susini, Tommaso ^a   Baldi, Feliciano ^a   Howard, Candace M ^a   Baldi, Alfonso ^a   Taddei, Gianluigi ^a   Massi, Daniela ^a   Rapi, Stefano ^a   Savino, Luciano ^a   Massi, Giambattista ^a   Giordano, Antonio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATHOGENESIS; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; TUMOR SUPPRESSOR GENE;

EID: 0031887422     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1085     Document Type: Article

References (59)

1. Pettersson F (ed): Annual Report on the Results of Treatment in Gynecological Cancer, vol 22. Stockholm, Sweden, Radiumhemmet, pp 65-82, 1985
2. Braly PS: Flow cytometry as prognostic factor in endometrial cancer - What does it add? Gynecol Oncol 58:145-147, 1995
3. MacMahon B: Risk factors for endometrial cancer. Gynecol Oncol 2:122-129, 1974
4. Boronow RC, Morrow CP, Creasman WT, et al: Surgical staging in endometrial cancer: Clinical pathological findings of a prospective study. Obstet Gynecol 63:825-832, 1984
5. DiSaia PJ, Creasman WT, Boronow RC, et al: Risk factors in recurrent patterns in stage I endometrial carcinoma. Am J Obstet Gynecol 151:1009-1015, 1985
6. Chambers SK, Kapp DS, Peschel RE, et al: Prognostic factors and sites of failure in FIGO stage I, grade 3 endometrial carcinoma. Gynecol Oncol 27:180-181, 1987
7. Creasman WT, Soper JT, McCarty KS Jr, et al: Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 151:922-932, 1985
8. Susini T, Rapi S, Savino L, et al: Prognostic value of flow cytometric deoxyribonucleic acid index in endometrial carcinoma: Comparison with other clinical-pathologic parameters. Am J Obstet Gynecol 170:527-534, 1994
9. Paggi MG, Baldi A, Bonetto F, et al: The retinoblastoma protein family in cell cycle and cancer. J Cell Biochem 62:418-430, 1996
10. Lee WH, Bookstein R, Hong F, et al: Human retinoblastoma susceptibility gene: Cloning, identification, and sequence. Science 235:1394-1399, 1987
11. Fung YK, Murphree AL, T'Ang A, et al: Structural evidence for the authenticity of the human retinoblastoma gene. Science 236:1657-1661, 1987
12. Huang HJ, Yee JK, Shew JY, et al: Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563-1566, 1988
13. Horowitz JM, Par SH, Bogenmann E, et al: Frequent inactivation of the retinoblastoma anti oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87:2775-2790, 1990
14. T'Ang A, Varley JM, Chakraborty S, et al: Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 242:263-266, 1988
15. Yokota J, Akiyama T, Fung YK, et al: Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3:471-475, 1988
16. Friend SH, Bernards R, Rogelj S, et al: A human segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646, 1986
17. Yaginuma Y, Katayama H, Kawai K, et al: Analysis of the retinoblastoma gene in human endometrial carcinoma. Obstet Gynecol 87:755-759, 1996
18. Sasano H, Comerford J, Silverberg SG, et al: An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. Cancer 66:2150-2154, 1990
19. Ambros RA, Vigna PA, Figge J, et al: Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer 73:1686-1692, 1994
20. Mayol X, Grana X, Baldi A, et al: Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene 8:2561-2566, 1993
21. Yeung R, Bell DW, Testa JR, et al: The retinoblastoma-related gene, RB2, maps to human chromosome 16q12 and rat chromosome 19. Oncogene 8:3465-3468, 1993
22. Baldi A, Boccia V, Claudio PP, et al: Genomic structure of the human retinoblastoma-related Rb2/p130 gene. Proc Natl Acad Sci USA 93:4629-4632, 1996
23. Li Y, Graham C, Lacy S, et al: The adenovirus E1A-associated 130-kD protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclin A and E. Genes Dev 7:2366-2377, 1993
24. Hannon GJ, Demetrick D, Beach D: Isolation of the Rb-related p130 through its interaction with cdk2 and cycling. Genes Dev 7:2378-2391, 1993
25. Baldi A, De Luca A, Claudio PP, et al: The Rb2/p130 gene product is a nuclear protein whose phosphorylation is cell cycle regulated. J Cell Biochem 59:402-408, 1995
26. Claudio PP, Howard CM, Baldi A, et al: p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p 107. Cancer Res 54:5556-5560, 1993
27. Claudio PP, De Luca A, Howard CM, et al: Functional analysis of pRb2/p130 interaction with cycling. Cancer Res 56:2003-2008, 1996
28. Baldi A, Esposito V, De Luca A, et al: Differential expression of the retinoblastoma gene family members in lung cancer. Clin Cancer Res 2:1239-1245, 1996
29. Baldi A, Esposito V, De Luca A, et al: Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin Cancer Res 3:1691-1697, 1997
30. Announcements: FIGO stage - 1988 revision. Gynecol Oncol 35:125-127, 1989
31. Pertile P, Baldi A, De Luca A, et al: Molecular cloning. expression, and developmental characterization of the murine retinoblastoma-related gene Rb2/p130. Cell Growth Diff 6:1659-1664, 1995
32. Shin DM, Lee JS, Lippman SM, et al: p53 expression: Predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 88:519-529, 1996
33. Silvestrini R, Benini E, Veneroni S, et al: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14:1604-1610, 1996
34. Fienberg SE: The Analysis of Cross-Classified Categorical Data. Cambridge, MA, MIT Press, 1977, pp 8-23
35. Zelterman D, Louis TA: Contingency tables in medical studies, in Bailar JC III, Mosteller F (eds): Medical Uses of Statistics (ed 2). Waltham, MA, NEJM Books, 1992, pp 293-310
36. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
37. Miller RG Jr: Survival Analysis. New York, NY, Wiley, 1981, pp 44-102
38. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
39. Aalders J, Abeler V, Kolstad P, et al: Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynecol 56:419-426, 1980
40. Kucera H, Vavra N, Weghaupt K: Benefit of external irradiation in pathologic stage I endometrial carcinoma: A prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol Oncol 38:99-104, 1990
41. De Luca A, MacLachlan TK, Bagella L, et al: A unique domain of pRb2/p130 acts as an inhibitor of cdk2 kinase activity. J Biol Chem 272:20971-20974, 1997
42. Howard CM, Giordano A: Neoplastic transformation: Oncogenes, tumor suppressors, cyclines, and cdks, in Vedeckis W (ed): Hormones and Cancer. Cambridge, MA, Birkauser, 1995, pp 3-41
43. Knudson AG: Retinoblastoma: Clues to human oncogenesis. Science 228:1028-1033, 1984
44. Cavenee WK, Hansen MF, Nordenskjold M, et al: Genetic origin of mutations predisposing to retinoblastoma. Science 228:501-503, 1985
45. Bienz-Tadmor B, Zakut-Houri R, Libresco S, et al: The 5′ region of the p53 gene: Evolutionary conservation and evidence for a negative regulatory element. EMBO J 4:3209-3213, 1985
46. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093, 1989
47. Pagano M, Tam SW, Theodoras AM, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685, 1995
48. Esposito V, Baldi A, De Luca A, et al: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57:3381-3385, 1997
49. Fujino T, Risinger JI, Collins K, et al: Allelotype of endometrial carcinoma. Cancer Res 54:4294-4298, 1994
50. Helin K, Holm K, Niebuhr A, et al: Loss of the retinoblastoma protein-related p 130 protein in small cell lung carcinoma. Proc Natl Acad Sci USA 94:6933-6938, 1997
51. Howard CM, Claudio PP, Giordano A: SV40 and human cancer, in Samuels SW, Upton AC (eds): Genes, Cancer and Ethics in the Work Environment. Beverly, MA, Occup Environ Med (in press)
52. De Luca A, Baldi A, Esposito V: The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 3:913-916, 1997
53. Carbone M, Rizzo P, Grimley PM: Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med 3:908-912, 1997
54. Massi G, Savino L, Susini T: Vaginal hysterectomy versus abdominal hysterectomy for the treatment of stage 1 endometrial adenocarcinoma. Am J Obstet Gynecol 174:1320-1326, 1996
55. Wingo PA, Huezo CM, Rubin GL, et al: The mortality risk associated with hysterectomy. Am J Obstet Gynecol 152:803-808, 1985
56. DiSaia PJ, Creasman WT: Adenocarcinoma of the uterus, in Clinical Gynecologic Oncology. St Louis, MO, Mosby-Year Book, 1993, pp 156-193
57. Pitkin RM: Vaginal hysterectomy in obese women. Obstet Gynecol 49:567-569, 1977
58. Peters WA III, Andersen WA, Thornton WN Jr, et al: The selective use of vaginal hysterectomy in the management of adenocarcinoma of the endometrium. Am J Obstet Gynecol 146:285-290, 1983
59. Massi G, Savino L, Susini T: Three classes of radical vaginal hysterectomy for treatment of endometrial and cervical carcinoma. Am J Obstet Gynecol 175:1576-1585, 1996